{"id":"NCT04491604","sponsor":"Krystal Biotech, Inc.","briefTitle":"Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB","officialTitle":"A Phase III Efficacy and Safety Study of Beremagene Geperpavec (B-VEC, Previously \"KB103\") for the Treatment of Dystrophic Epidermolysis Bullosa (DEB)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-08-17","primaryCompletion":"2021-10-29","completion":"2022-01-14","firstPosted":"2020-07-29","resultsPosted":"2023-02-17","lastUpdate":"2023-02-17"},"enrollment":31,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Dystrophic Epidermolysis Bullosa","Recessive Dystrophic Epidermolysis Bullosa","Dominant Dystrophic Epidermolysis Bullosa"],"interventions":[{"type":"BIOLOGICAL","name":"Topical Beremagene Geperpavec","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"B-VEC","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To determine whether administration of topical B-VEC improves wound healing as compared to placebo, and to evaluate durability, repeat dosing (Primary Endpoint) and further obtain safety and tolerability data.","primaryOutcome":{"measure":"Primary Wound With Complete Wound Healing (100% Wound Closure) on Weeks 22 and 24 or Weeks 24 and 26","timeFrame":"26 weeks post-baseline","effectByArm":[{"arm":"B-VEC","deltaMin":20.9,"sd":null},{"arm":"Placebo","deltaMin":6.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.00192"}]},"eligibility":{"minAge":"6 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":3,"countries":["United States"]},"refs":{"pmids":["36516090"],"seeAlso":["https://www.krystalbio.com/patients-and-families/patient-advocacy/"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":31},"commonTop":["Pruritus","Chills","Squamous cell carcinoma","Erythema","Rash"]}}